Lantheus Holdings enters the back half of May with a striking dynamic: the stock has rallied nearly 19% over the past month to $100.06, analysts have spent three weeks lifting targets in sequence, yet short sellers have barely flinched.
The analyst story is the clearest signal right now. Every recent action has been a raise, with no cuts and no downgrades since a lone Jones Trading downgrade back in February. Mizuho lifted its target to $115 just this week, maintaining Outperform, while Truist Securities and Citizens had both moved to $115 earlier in May after Q1 results. The pattern across those three firms is consistent: a strong print triggers a target lift, but the rating itself never needed upgrading because conviction was already in place. The consensus mean sits at $105.23, fractionally above where the stock closed on Tuesday — meaning the Street is now roughly fairly priced at the midpoint, with a handful of individual targets still pointing higher.
Short interest tells a notably unexcited story given the rally. At 8.1% of free float — roughly 5.36 million shares — the short position is real but not extreme, and it edged lower by around 3.3% on the week. More telling is the lending environment: availability is running at 457%, meaning there are more than four shares available to borrow for every share currently shorted. That is well inside the loose range and near the high end of recent readings. Cost to borrow is 0.59%, up 7% on the week but still trivially low in absolute terms. There is no meaningful squeeze pressure, and no evidence of fresh short accumulation despite the stock pushing through $100. The ORTEX short score of 56 is mid-range and has actually eased slightly over the past few sessions.
Options positioning has grown modestly more defensive over the past two weeks. The put/call ratio has climbed to 0.62 from lows below 0.46 in early May, now running about one standard deviation above its 20-day average of 0.55. That is notable directionally — hedging appetite ticked up just as the stock approached the $100 level — but the absolute reading is still well below the 52-week high of 0.89. The shift looks more like routine profit protection after a strong month than a bearish re-positioning.
The fundamental debate is straightforward. Bulls point to the EPS beat track record — the surprise factor ranks in the 85th percentile — and to a 12-month forward EPS trajectory that sits more than 100% above last year's level, giving LNTH a growth score near the top of its peer group. The May 7 Q1 print delivered an 8% next-day gain and a 12% five-day follow-through, the kind of reaction that keeps target raisers busy. Bears anchor on concentration risk: DEFINITY and PYLARIFY together account for over 80% of sales, and any reimbursement pressure or competitive entry into the PET imaging space would hit revenues with limited offset elsewhere. Valuation has compressed a touch on a forward EV/EBITDA basis — the multiple has drifted lower by about 0.85x over the past 30 days even as the price rose, reflecting the scale of the earnings revision cycle — but a price-to-book above 13x is not cheap.
The next scheduled print is August 6. Between now and then, the key variable is whether analysts who have been steadily repricing targets upward find their $115 ceiling confirmed by mid-year guidance, or whether the stock's arrival at the consensus mean triggers the first round of "priced in" commentary that has so far been absent from the tape.
See the live data behind this article on ORTEX.
Open LNTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
